Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors

Pediatric Blood and Cancer

Volumn 60, Issue 9, 2013, Pages 1552-1556

  Kaste, Sue C ^a,b   Kaufman, Robert A ^a,b   Gajjar, Amar ^a,b   Broniscer, Alberto ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antiangiogenesis agents; Chemotherapy; Magnetic resonance imaging; Pediatric brain tumors; Skeletalgenesis; VEGF

Indexed keywords

DASATINIB; VANDETANIB;

ADOLESCENT; ARTICLE; BONE NECROSIS; BRAIN TUMOR; CANCER GROWTH; CANCER RADIOTHERAPY; CHILD; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KNEE; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PONTINE GLIOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SKELETON; TREATMENT DURATION;

ANTIANGIOGENESIS AGENTS; CHEMOTHERAPY; MAGNETIC RESONANCE IMAGING; PEDIATRIC BRAIN TUMORS; SKELETALGENESIS; VEGF;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; INFANT; KNEE JOINT; MAGNETIC RESONANCE IMAGING; MALE; OSTEONECROSIS; PIPERIDINES; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; THIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84878986126     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24536     Document Type: Article

References (39)

1. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-745.
2. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524.
3. Zondor SD, Medina PJ. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004; 38:1258-1264.
4. Widemann BC, Kim A, Fox E, et al. A phase I trial and pharmacokinetic study of the Raf kinase and receptor tyrosine kinase inhibitor sorafenib in children with refractory solid tumors or refractory leukemias. Clin Cancer Res 2012; 18:6011-6022.
5. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A children's oncology group study. J Clin Oncol 2008; 26:399-405.
6. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: Critical review of clinical trials. Lancet Oncol 2006; 7:241-248.
7. Broniscer A, Baker JN, Baker SJ, et al. Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer 2010; 116:4632-4637.
8. Kleihues P, Burger PC, Aldape KD, et al. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumors of the central nervous system. Lyon: IARC Press; 2007. pp. 33-49.
9. Broniscer A, Baker JN, Tagen M, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 2010; 28:4762-4768.
10. Broniscer A, Baker SD, Baker JN, et al. A phase I study of the combination of vandetanib and dasatinib administered during and after radiotherapy (RT) in children. In: 2011. p. iii98.
11. Zelzer E, Olsen BR. Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. Curr Top Dev Biol 2005; 65:169-187.
12. Patyna S, Arrigoni C, Terron A, et al. Nonclinical safety evaluation of sunitinib: A potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Toxicol Pathol 2008; 36:905-916.
13. Kabata T, Matsumoto T, Yagishita S, et al. Vascular endothelial growth factor in rabbits during development of corticosteroid-induced osteonecrosis: A controlled experiment. J Rheumatol 2008; 35:2383-2390.
14. Smith AR, Hennessy JM, Kurth MA, et al. Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome. Pediatr Blood Cancer 2008; 51:418-420.
15. Modak S, Cheung NK, Abramson SJ, et al. Lack of early bevacizumab-related skeletal radiographic changes in children with neuroblastoma. Pediatr Blood Cancer 2009; 52:304-305.
16. Laor T, Chun GF, Dardzinski BJ, et al. Posterior distal femoral and proximal tibial metaphyseal stripes at MR imaging in children and young adults. Radiology 2002; 224:669-674.
17. Karimova EJ, Kaste SC. MR imaging of osteonecrosis of the knee in children with acute lymphocytic leukemia. Pediatr Radiol 2007; 37:1140-1146.
18. Gururangan S, Chi SN, Young PT, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A pediatric brain tumor consortium study. J Clin Oncol 2010; 28:3069-3075.
19. Grunewald TG, Greulich N, Kontny U, et al. Targeted therapeutics in treatment of children and young adults with solid tumors: An expert survey and review of the literature. Klin Padiatr 2012; 224:124-131.
20. Inaba H, Rubnitz JE, Coustan-Smith E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011; 29:3293-3300.
21. Thapa MM, Iyer RS, Khanna PC, et al. MRI of pediatric patients: Part 1, normal and abnormal cartilage. AJR Am J Roentgenol 2012; 198:W450-W455.
22. Strouse PJ. Overview of musculoskeletal imaging. In: Slovis TL, Caffey J, editors. Caffey's pediatric diagnostic imaging. Mosby/Elsevier; 2008. p. 2831.
23. Imhof H, Breitenseher M, Trattnig S, et al. Imaging of avascular necrosis of bone. Eur Radiol 1997; 7:180-186.
24. Zibis AH, Karantanas AH, Roidis NT, et al. The role of MR imaging in staging femoral head osteonecrosis. Eur J Radiol 2007; 63:3-9.
25. Laor T, Jaramillo D. MR imaging insights into skeletal maturation: What is normal? Radiology 2009; 250:28-38.
26. Trueta J. The normal vascular anatomy of the human femoral head during growth. J Bone Joint Surg Br 1957; 39-B:358-394.
27. Haines RW. Cartilage canals. J Anat 1933; 68:45-64.
28. Hughes LO, Aronson J, Smith HS. Normal radiographic values for cartilage thickness and physeal angle in the pediatric hip. J Pediatr Orthop 1999; 19:443-448.
29. Rissech C, Schaefer M, Malgosa A. Development of the femur-Implications for age and sex determination. Forensic Sci Int 2008; 180:1-9.
30. DeLuca F. Impaired growth plate chondrogenesis in children with chronic illnesses. Pediatr Res 2006; 59:625-629.
31. Silvestrini G, Mocetti P, Di GR, et al. Localization of the glucocorticoid receptor mRNA in cartilage and bone cells of the rat. An in situ hybridization study. Eur J Histochem 2003; 47:245-252.
32. Hall AP, Westwood FR, Wadsworth PF. Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Toxicol Pathol 2006; 34:131-147.
33. Jaramillo D, Hoffer FA. Cartilaginous epiphysis and growth plate: Normal and abnormal MR imaging findings. AJR Am J Roentgenol 1992; 158:1105-1110.
34. Chrysis D, Ritzen EM, Savendahl L. Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes. J Endocrinol 2003; 176:331-337.
35. Fangusaro J, Gururangan S, Jakacki RI, et al. Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent central nervous system (CNS) tumors. J Clin Oncol 2013; 31:e24-e27. Doi: 10.1200/JCO.2012.43.6733.
36. Karimova EJ, Rai SN, Howard SC, et al. Femoral head osteonecrosis in pediatric and young adult patients with leukemia or lymphoma. J Clin Oncol 2007; 25:1525-1531.
37. Friedrich KM, Reiter G, Kaiser B, et al. High-resolution cartilage imaging of the knee at 3T: Basic evaluation of modern isotropic 3D MR-sequences. Eur J Radiol 2011; 78:398-405.
38. Milewski MD, Smitaman E, Moukaddam H, et al. Comparison of 3D vs. 2D fast spin echo imaging for evaluation of articular cartilage in the knee on a 3T system scientific research. Eur J Radiol 2012; 81:1637-1643.
39. Mosher TJ. Musculoskeletal imaging at 3T: Current techniques and future applications. Magn Reson Imaging Clin N Am 2006; 14:63-76.